Market Insight - Avoiding bribery risk 2: world focus
This article was originally published in Scrip
Executive Summary
In the second of two Market Insight articles highlighting to pharma the dangers of bribery risk, Jeremy Cole and Marc Dalby explain why regulators are taking an increasingly hard line on multinationals and their more dubious business relationships